Silicone punctal plugs as an adjunctive therapy for open-angle glaucoma and ocular hypertension

Clinical and Experimental Optometry

Volumn 94, Issue 5, 2011, Pages 438-442

  Opitz, Dominick L ^a,b   Tung, Sherman ^a   Jang, Unsun Sarah ^a   Park, Jenny J ^a  

^a ILLINOIS COLLEGE OF OPTOMETRY   (United States)

^b Midwest Eye Professionals   (United States)

Author keywords

Disease management; Glaucoma; Ocular hypertension; Patient compliance; Punctal plugs; Travoprost

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE; SILICONE DERIVATIVE; TRAVOPROST;

ADULT; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IMPLANTATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; OPEN ANGLE GLAUCOMA; PROSTHESES AND ORTHOSES;

ADULT; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; COMBINED MODALITY THERAPY; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; PROSTHESES AND IMPLANTS; PROSTHESIS IMPLANTATION; SILICONES;

EID: 80052023798     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2010.00587.x     Document Type: Article

References (31)

1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK etal. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713.
2. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-1953.
3. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-440.
4. Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505.
5. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279.
6. Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk M, Trope FE. Canadian Glaucoma Study. 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008; 126: 1030-1139.
7. Glaucoma Panel, Preferred Practice Patterns Committee. Preferred practice pattern: primary open angle glaucoma. Limited revision. San Francisco: American Academy of Ophthalmology, 2008. Available at. Cited 16 Mar 2010.
8. Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, Kelly S etal. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol 2009; 3: 447-456.
9. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost and latanoprost. Curr Med Res Opin 2006; 22: 971-976.
10. Kosoko O, Quigley HA, Vitale S, Enger C, Kerrigan L, Tielsch JM. Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic. Ophthalmology 1998; 105: 2105-2111.
11. Olthoff CMG, Schouten JSAG, van de Borne BW, Webers CAB. Non-compliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology 2005; 112: 953-961.
12. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004; 137 suppl 1: 3-12.
13. Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006; 141 suppl 1: 28-33.
14. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995; 26: 233-236.
15. Stewart WC, Konstas AGP, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004; 20: 461-469.
16. Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther 2002; 18: 401-409.
17. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol 1990; 74: 477-480.
18. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12: 393-398.
19. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005; 112: 863-868.
20. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000; 130: 832-833.
21. Huang TC, Lee DA. Punctal occlusion and topical medications for glaucoma. Am J Ophthalmol 1989; 107: 151-155.
22. Bartlett JD, Boan K, Corliss D, Gaddie IB. Efficacy of silicone punctal plug as adjuncts to topical pharmacotherapy of glaucoma-a pilot study. J Am Optom Assoc 1996; 67: 664-668.
23. Zimmerman TJ, Sharir M, Nardin GF. Therapeutic index of pilocarpine, carbachol and timolol with nasolacrimal occlusion. Am J Ophthalmol 1992; 114: 1-7.
24. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984; 102: 551-553.
25. Kwitko GM, Shin DH, Ahn BH, Hong YJ. Bilateral effects of long-term monocular timolol therapy. Am J Ophthalmol 1987; 104: 591-594.
26. World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research involving human subjects. Available from: Cited 7 January 2011.
27. Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2% and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 2009; 116: 1719-1724.
28. Juzych MS, Chopra V, Banitt MR, Hughes BA, Kim C, Goulas MT, Shin DH. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology 2004; 111: 1853-1859.
29. Van Buskirk EM. The compliance factor. Am J Ophthalmol 1986; 101: 609-610.
30. Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J etal. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004; 111: 1627-1635.
31. Serle JB, Toor A, Fahim MM, Polikoff LA, Ellison J. The effect of varying dosing intervals on the efficacy of intraocular pressure lowering drugs. Invest Ophthalmol Vis Sci 2004; 45: E abstract 971.